10.14.22
Curology has appointed Heather Wallace as its new Chief Executive Officer. Dr. David Lortscher has been CEO since he co-founded the company in 2012—and now will step into a new role as Executive Chair of the Board.
Curology is leading company in personalized, prescription skincare. The appointment became effective as of September 26th.
Lortscher transformed Curology from a startup into the largest player in the teledermatology space, serving more than 4 million patients. The brand's products tackle everything from clearing acne and dark spots to fighting rosacea and wrinkles.
The company saw accelerated growth during the pandemic as consumers shifted more broadly to telemedicine.
This past quarter, Curology reached the milestone of profitability, and the company is projected to generate over $200 million in revenue in 2022, a 75% compound annual growth rate over the past five years.
Lortscher comments, "I decided to make this transition because the skills you need to successfully found a company are very different from the skills you need to grow an established company to its full potential."
He continues, "As a profitable company and as the leading player in personalized skincare, we have a tremendous amount of opportunity ahead of us. Heather's track record of driving profitable growth at scale, her deep experience in both beauty and healthcare, and her genuine belief in Curology's mission make her our ideal next CEO as we expand into different channels and meet the skincare needs of even more people."
Curology was the first personalized prescription skincare company in the beauty industry. With customized products for acne, anti-aging, and more, its brands Curology and Agency have redefined what it means to offer skincare solutions tailored to each consumer's unique needs.
Wallace previously served as President of the Americas at Revlon, where she turned around Revlon Cosmetics in the US to deliver market share growth and improved profitability with a focus on digitalization.
Wallace also has a background in healthcare, having successfully led multiple prescription and non-prescription business lines at Novartis over the course of 10 years.